- Home
- / Esperion Therapeutics
Esperion Therapeutics
Stock Price
$2.1
2024-10-29
Market Capitalization
$416 M
2024-10-29
Revenue
$403.1 M
FY, 2025
Esperion Therapeutics Summary
Company Summary
- Overview
- Esperion Therapeutics is a pharmaceutical company. It specializes in developing and commercializing oral, low‑density lipoprotein cholesterol (LDL-C) therapies for patients with hypercholesterolemia.
- Type
- Public
- Status
- Active
- Founded
- 2008
- HQ
- Ann Arbor, MI, US | view all locations
- Website
- http://www.esperion.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Richard Bartram, Chief Financial Officer
Joanne Micale Foody, Chief Medical Officer
Benjamin O. Looker, General Counsel
Operating MetricsView all
Office Space, sq. ft.
19.4K
FY, 2020
Patent Applications (Foreign)
75
FY, 2020
Patents Issued (Foreign)
20
FY, 2020
LocationsView all
1 location detected
Ann Arbor, MI HQ
United States
3891 Ranchero Dr
Esperion Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $80.1M
- Net income (Q1, 2026)
- ($25.2M)
- Cash (Q1, 2026)
- $156.2M
- EBIT (Q1, 2026)
- ($6.6M)
- Enterprise value
- $512.4M